ERBB2 and colorectal carcinoma: Lapatinib, the FDA-approved epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitor, is an example as it was found to improve the apoptotic effect of TRAIL and TRAIL-Rs agonists, such as mapatumumab and lexatumumab in CRC cells via upregulation of DR4 and 5 [23].